Weil Guides Bard In $200M Deal For Hemostat Maker Medafor

Law360, New York (August 19, 2013, 2:34 PM EDT) -- New Jersey-based C.R. Bard Inc. will pay some $200 million in cash to purchase Minneapolis-based hemostat firm Medafor Inc. through Bard's specialized surgical procedures unit Davol Inc., the companies said Monday.

Bard will pay the $200 million when the deal closes but may also pay up to $80 million when certain revenue milestones until June 2015 are reached, according to the companies. The deal, which requires regulatory approvals and a blessing from Medafor shareholders, is expected to close by the end of the year.

“With the...
To view the full article, register now.